Atlas Bio secures 12.5M dollars in Creandum led funding
Swiss AI start up Atlas Bio has raised 12.5 million dollars in a funding round led by Creandum. The company uses virtual patients and foundation models to replace traditional Phase II drug trials and animal testing with rapid simulations.
Insights:
Atlas Bio secured $12.5M in funding on Tuesday, led by venture capital firm Creandum, to advance its virtual patient drug trial platform. The financing enables the Switzerland-based start-up to expand its AI simulation models. The funding round gives investors a fresh entry point into the emerging computational drug discovery sector.
